Tysabri makers report no new PML cases in drug evaluation

Share this article:
Biogen Idec and Elan announced that findings from their safety evaluation of the suspended drug Tysabri (natalizumab) in patients with Crohn's disease and rheumatoid arthritis, resulted in no new confirmed cases of the rare brain disease progressive multifocal leukoencephalopathy (PML).
 Both companies reported similarly positive results in August in a screening of nearly 2,000 sufferers of multiple sclerosis, who took the drug in clinical trials.
In their statement, Biogen and Elan said the safety evaluation into PML risks among patients in clinical trials is now complete.
Biogen and Elan voluntarily suspended Tysabri from the U.S. market in February after three confirmed cases of PML, two of which were fatal, were reported in patients taking the drug.
In a Wall Street Journal report, analysts said they expected a restricted return of Tysabri to the market in several months rather than in years.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters